Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Margolis

Showing results (371-380 of 392) with videos related to

Pageof 40
Sort By:
European Urology|March 30, 2013
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working GroupCaroline M Moore, Veeru Kasivisvanathan, Scott Eggener, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionSusan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
The Lancet. HIV|April 1, 2021
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR studyChloe Orkin, Shinichi Oka, Patrick Philibert, et al.
Lancet (London, England)|December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
Journal of Applied Clinical Medical Physics|March 19, 2026
Post hoc estimation of a quantitative restriction spectrum imaging biomarker for prostate cancer detection using conventional MRIDeondre D Do, Christopher C Conlin, Aditya Bagrodia, et al.
AJR. American Journal of Roentgenology|July 16, 2025
Evaluating Artificial Intelligence-Assisted Prostate Biparametric MRI Interpretation: An International Multireader StudyDavid G Gelikman, Enis C Yilmaz, Stephanie A Harmon, et al.
European Urology Open Science|January 15, 2025
Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate CancerMadison T Baxter, Christopher C Conlin, Aditya Bagrodia, et al.
European Urology Open Science|February 16, 2026
Deep Learning Artificial Intelligence and Restriction Spectrum Imaging for Patient-level Detection of Clinically Significant Prostate Cancer on Biparametric Magnetic Resonance ImagingYuze Song, Mariluz Rojo Domingo, Christopher C Conlin, et al.
Nature Genetics|August 29, 2018
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsDiana Miao, Claire A Margolis, Natalie I Vokes, et al.
Nature Medicine|June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Pageof 40

Showing results (371-380 of 392) with videos related to

Sort By:
Pageof 40
European Urology|March 30, 2013
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working GroupCaroline M Moore, Veeru Kasivisvanathan, Scott Eggener, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionSusan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
The Lancet. HIV|April 1, 2021
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR studyChloe Orkin, Shinichi Oka, Patrick Philibert, et al.
Lancet (London, England)|December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
Journal of Applied Clinical Medical Physics|March 19, 2026
Post hoc estimation of a quantitative restriction spectrum imaging biomarker for prostate cancer detection using conventional MRIDeondre D Do, Christopher C Conlin, Aditya Bagrodia, et al.
AJR. American Journal of Roentgenology|July 16, 2025
Evaluating Artificial Intelligence-Assisted Prostate Biparametric MRI Interpretation: An International Multireader StudyDavid G Gelikman, Enis C Yilmaz, Stephanie A Harmon, et al.
European Urology Open Science|January 15, 2025
Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate CancerMadison T Baxter, Christopher C Conlin, Aditya Bagrodia, et al.
European Urology Open Science|February 16, 2026
Deep Learning Artificial Intelligence and Restriction Spectrum Imaging for Patient-level Detection of Clinically Significant Prostate Cancer on Biparametric Magnetic Resonance ImagingYuze Song, Mariluz Rojo Domingo, Christopher C Conlin, et al.
Nature Genetics|August 29, 2018
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsDiana Miao, Claire A Margolis, Natalie I Vokes, et al.
Nature Medicine|June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Pageof 40